InflaRx (IFRX) Share-based Compensation (IS) (2017 - 2019)
InflaRx's (IFRX) quarterly Share-based Compensation (IS) came in at $1.3 million in Q4 2019, down 64.03% year-on-year from $3.5 million in Q4 2018, and down 36.82% quarter-over-quarter from $2.0 million in Q3 2019.
InflaRx (IFRX) Share-based Compensation (IS) (2017 - 2019) Analysis & Trends
InflaRx has disclosed Share-based Compensation (IS) across 3 years of filings, most recently posting $1.3 million for Q4 2019.
- Share-based Compensation (IS) for Q4 2019 came in at $1.3 million, down 64.03% year-over-year; the trailing twelve-month figure through Dec 2019 was $10.0 million (down 29.77% YoY), and the FY2019 annual result was $7.6 million, down 45.17% from the prior year.
- Share-based Compensation (IS) came in at $1.3 million for Q4 2019 at InflaRx, down from $2.0 million in the prior quarter.
- In the past five years, Share-based Compensation (IS) ranged from a high of $4.4 million in Q2 2019 to a low of $695637.5 in Q3 2017.
- The 3-year median for Share-based Compensation (IS) is $2.6 million (2017), against an average of $2.5 million.
- Across the five-year window, Share-based Compensation (IS) surged 412.6% in 2018 and slumped 64.03% in 2019, its largest moves.
- InflaRx's Share-based Compensation (IS) stood at $2.9 million in 2017, then advanced by 20.96% to $3.5 million in 2018, then plunged by 64.03% to $1.3 million in 2019.
- The last three Share-based Compensation (IS) figures came in at $1.3 million (Q4 2019), $2.0 million (Q3 2019), and $4.4 million (Q2 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1.45 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 892,057.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 14.90 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Sep 30, 2019 | 2.00 Mn |
| Sep 30, 2019 | 2.00 Mn |
| Jun 30, 2019 | 4.37 Mn |
| Jun 30, 2019 | 4.37 Mn |
| Mar 31, 2019 | 2.38 Mn |
| Mar 31, 2019 | 2.38 Mn |
| Dec 31, 2018 | 3.52 Mn |
| Dec 31, 2018 | 3.52 Mn |
| Sep 30, 2018 | 3.57 Mn |
| Sep 30, 2018 | 3.57 Mn |
| Jun 30, 2018 | 3.58 Mn |
| Jun 30, 2018 | 3.58 Mn |
| Mar 31, 2018 | 3.61 Mn |
| Mar 31, 2018 | 3.61 Mn |
| Dec 31, 2017 | 2.91 Mn |
| Dec 31, 2017 | 2.91 Mn |
| Sep 30, 2017 | 695,637.45 |
| Sep 30, 2017 | 695,637.45 |